Journal of Chemotherapy,
Год журнала:
2024,
Номер
unknown, С. 1 - 24
Опубликована: Дек. 22, 2024
Immunotherapy
has
been
advanced
through
multiple
approaches,
including
immunogenic
cytokines,
monoclonal
antibodies,
therapeutic
vaccinations,
adoptive
cell
transfer,
stem
transplantation,
and
oncolytic
viruses.
This
review
analyses
various
strategies
in
genomics,
transcriptomics,
single-cell
techniques,
computational
analysis,
big
data,
imaging
technologies
for
the
identification
of
tumour
microbiota
microenvironments.
is
becoming
acknowledged
as
a
feasible
cancer
treatment
method,
facilitating
innovative
medicines
personalized
medicine
techniques.
Journal of Translational Medicine,
Год журнала:
2025,
Номер
23(1)
Опубликована: Фев. 10, 2025
Abstract
Background
Epstein-Barr
virus
(EBV)
is
an
oncovirus
belonging
to
the
herpesvirus
family,
associated
with
pathogenesis
of
multiple
malignancies,
particularly
Burkitt
lymphoma
(BL).
The
remains
latent
in
host
cells
and
plays
a
critical
role
tumor
progression
through
various
mechanisms.
A
key
glycoprotein,
gp350,
expressed
during
lytic
phase
EBV,
instrumental
viral
entry
into
B
presents
unique
antigenic
target,
making
it
promising
candidate
for
immunotherapeutic
approaches,
such
as
chimeric
antigen
receptor
T-cell
(CAR-T)
therapy.
Methods
In
this
study,
we
engineered
CAR-T
targeted
against
gp350
glycoprotein
assessed
their
therapeutic
potential
series
vitro
vivo
experiments.
efficacy
gp350-CAR-T
was
evaluated
by
comparing
cytotoxic
effects
both
EBV-positive
-negative
cell
lines.
We
utilized
xenograft
model
monitor
impact
administration
on
overall
survival.
Results
demonstrated
potent
cytotoxicity
specifically
our
model,
resulted
significant
inhibition
growth,
highlighting
capability
effectively
target
eliminate
lymphomas.
This
selectivity
underscores
utilizing
specific
immunotherapy.
Conclusion
Our
findings
advocate
clinical
application
gp350-directed
therapy
prospective
treatment
strategy
patients
relapsed
or
refractory
tumors.
Given
encouraging
preclinical
results,
further
research
warranted
optimize
production
processes
extend
other
EBV-associated
paving
way
improved
outcomes
affected
patient
populations.
Theranostics,
Год журнала:
2024,
Номер
14(16), С. 6249 - 6267
Опубликована: Янв. 1, 2024
:
CD39,
a
key
ectonucleotidase
that
drives
adenosine
production,
acts
as
critical
immunosuppressive
checkpoint
in
cancer.
Although
it
has
shown
promise
therapeutic
target,
clinical
trials
are
demonstrating
the
need
for
more
potent
targeting
approaches.
This
is
driving
innovation
towards
development
of
novel
antibodies
and
exploration
strategic
combinations
with
range
immunotherapies.
Current Issues in Molecular Biology,
Год журнала:
2025,
Номер
47(2), С. 90 - 90
Опубликована: Янв. 31, 2025
Chimeric
antigen
receptor-T
(CAR-T)
cell
therapy
has
demonstrated
impressive
efficacy
in
the
treatment
of
blood
cancers;
however,
its
effectiveness
against
solid
tumors
been
significantly
limited.
The
differences
arise
from
a
range
difficulties
linked
to
tumors,
including
an
unfriendly
tumor
microenvironment,
variability
within
and
barriers
CAR-T
infiltration
longevity
at
location.
Research
shows
that
reasons
for
decreased
cells
treating
are
not
well
understood,
highlighting
ongoing
need
strategies
address
these
challenges.
Current
frequently
incorporate
combinatorial
therapies
designed
boost
functionality
enhance
their
capacity
effectively
target
tumors.
However,
remain
testing
phase
necessitate
additional
validation
assess
potential
benefits.
CAR-NK
(natural
killer),
CAR-iNKT
(invariant
natural
killer
T),
CAR-M
(macrophage)
emerging
as
promising
Recent
studies
highlight
construction
optimization
cells,
emphasizing
overcome
unique
challenges
posed
by
such
hypoxia
metabolic
barriers.
This
review
focuses
on
CAR
The
tumor
microenvironment
(TME)
represents
a
heterogeneous,
complicated
ecosystem
characterized
by
intricate
interactions
between
cells
and
immune
cells.
During
the
past
decade,
especially
T
were
found
to
play
an
important
role
in
progression
of
many
related
checkpoints
drugs
created.
In
recent
years,
more
scientists
revealed
critical
B-cells
within
TME,
particularly
various
populations
non-malignant
B
Some
studies
indicated
that
may
exert
'double-edged
sword'
solid
tumors.
However,
there
has
been
comparatively
less
focus
on
hematologic
malignancies.
this
review,
we
development
summarized
its
functions
antitumor
immunity
with
emphasis
elucidating
roles
potential
mechanisms
diseases
including
classical
Hodgkin's
lymphoma,
non-Hodgkin's
B-cell
T-cell
leukemia
multiple
myeloma.
Journal of Experimental & Clinical Cancer Research,
Год журнала:
2025,
Номер
44(1)
Опубликована: Апрель 25, 2025
Abstract
This
review
discusses
reprogramming
the
breast
tumor
immune
microenvironment
from
an
immunosuppressive
cold
state
to
immunologically
active
hot
state.
A
complex
interplay
is
revealed,
in
which
accumulation
of
metabolic
byproducts—such
as
lactate,
reactive
oxygen
species
(ROS),
and
ammonia—is
shown
impair
T-cell
function
promote
escape.
It
demonstrated
that
(TME)
dominated
by
cytokines,
including
interleukin-10
(IL-10),
transforming
growth
factorβ
(TGFβ),
IL-35.
Notably,
IL-35
produced
regulatory
T
cells
cancer
cells.
The
conversion
conventional
into
IL-35-producing
induced
cells,
along
with
inhibition
pro-inflammatory
cytokine
secretion,
contributes
suppression
anti-tumor
immunity.
further
key
checkpoint
molecules—such
PD-1,
PDL1,
CTLA-4,
TIM-3,
LAG-3,
TIGIT—are
upregulated
within
TME,
leading
Tcell
exhaustion
diminished
responses.
blockade
these
checkpoints
restore
functionality
proposed
a
strategy
convert
tumors
ones
robust
effector
cell
infiltration.
therapeutic
potential
chimeric
antigen
receptor
(CAR)T
therapy
also
explored,
targeting
specific
tumor-associated
antigens,
such
glycoproteins
tyrosine
kinases,
highlighted.
suggested
CART
efficacy
can
be
enhanced
combining
inhibitors
other
immunomodulatory
agents,
thereby
overcoming
barriers
imposed
TME.
Moreover,
role
microbiome
regulating
estrogen
metabolism
systemic
inflammation
reviewed.
Alterations
gut
microbiota
are
affect
microbiome-based
interventions
additional
means
facilitate
cold-to-hot
transition.
concluded
immunological
pathways
underpin
suppression—through
combination
strategies
involving
blockade,
therapies,
modulation—the
TME
achieved.
anticipated
enhance
infiltration
function,
improving
overall
immunotherapies
better
clinical
outcomes
for
patients.
